Organovo (ONVO) 10-Q 10 Feb 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Dec. 31, 2019	Feb. 01, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Trading Symbol	ONVO
Entity Registrant Name	ORGANOVO HOLDINGS, INC.
Entity Central Index Key	0001497253
Current Fiscal Year End Date	--03-31
Entity Filer Category	Accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		130,497,563
Entity File Number	001-35996
Entity Current Reporting Status	Yes
Entity Tax Identification Number	27-1488943
Entity Address, Address Line One	440 Stevens Ave
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Solana Beach
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92075
City Area Code	858
Local Phone Number	224-1000
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.001 par value
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Mar. 31, 2019
Current Assets
Cash and cash equivalents	$ 30,467	$ 36,477
Accounts receivable	165	503
Grant receivable	0	55
Inventory, net	0	490
Prepaid expenses and other current assets	474	1,049
Total current assets	31,106	38,574
Fixed assets, net	0	1,832
Restricted cash	79	79
Other assets, net	127	138
Total assets	31,312	40,623
Current Liabilities
Accounts payable	822	628
Accrued expenses	1,536	2,549
Deferred revenue	0	525
Deferred rent	0	35
Total current liabilities	2,358	3,737
Deferred rent, net of current portion	0	588
Total liabilities	2,358	4,325
Commitments and Contingencies	0	0
Stockholders’ Equity
Common stock, $0.001 par value; 200,000,000 shares authorized, 130,497,563 and 124,015,429 shares issued and outstanding at December 31, 2019 and March 31, 2019, respectively	130	124
Additional paid-in capital	305,566	296,929
Accumulated deficit	(276,742)	(260,755)
Total stockholders’ equity	28,954	36,298
Total Liabilities and Stockholders’ Equity	$ 31,312	$ 40,623

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Mar. 31, 2019
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	130,497,563	124,015,429
Common stock, shares outstanding	130,497,563	124,015,429

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Revenues
Total Revenues	$ 298	$ 779	$ 2,196	$ 2,411
Cost of revenues	13	136	328	381
Research and development expenses	145	3,782	5,413	10,348
Selling, general and administrative expenses	5,374	3,387	15,037	11,794
Total costs and expenses	5,532	7,305	20,778	22,523
Loss from Operations	(5,234)	(6,526)	(18,582)	(20,112)
Other Income (Expense)
Gain (loss) on fixed asset disposals	25	(65)	111	(63)
Gain on lease termination	525	0	525	0
Interest income	127	192	507	526
Other Income (Expense)	1,187	0	1,454	0
Total Other Income	1,864	127	2,597	463
Income Tax Expense	0	0	(2)	(3)
Net Loss	(3,370)	(6,399)	(15,987)	(19,652)
Comprehensive Loss	$ (3,370)	$ (6,399)	$ (15,987)	$ (19,652)
Net loss per common share—basic and diluted	$ (0.03)	$ (0.06)	$ (0.12)	$ (0.17)
Weighted average shares used in computing net loss per common share—basic and diluted	130,466,234	116,256,561	129,234,731	113,991,794
Products and Services [Member]
Revenues
Total Revenues	$ 228	$ 670	$ 2,055	$ 1,709
Collaborations and Licenses [Member]
Revenues
Total Revenues	70	43	89	128
Grants [Member]
Revenues
Total Revenues	$ 0	$ 66	$ 52	$ 574

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Mar. 31, 2018	$ 44,586	$ 111	$ 278,595	$ (234,120)
Beginning balance, Shares at Mar. 31, 2018		111,033,000
Issuance of common stock under employee and director stock option, RSU, and purchase plans	(103)	$ 0	(103)	0
Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares		200,000
Issuance of common stock from public offering, net	3,010	$ 2	3,008	0
Issuance of common stock from public offering, Shares		2,085,000
Stock-based compensation expense	1,279	$ 0	1,279	0
Net loss	(7,416)	0	0	(7,416)
Ending balance at Jun. 30, 2018	41,356	$ 113	282,779	(241,536)
Ending balance, Shares at Jun. 30, 2018		113,318,000
Beginning balance at Mar. 31, 2018	44,586	$ 111	278,595	(234,120)
Beginning balance, Shares at Mar. 31, 2018		111,033,000
Net loss	(19,652)
Ending balance at Dec. 31, 2018	35,675	$ 118	289,329	(253,772)
Ending balance, Shares at Dec. 31, 2018		117,770,000
Beginning balance at Jun. 30, 2018	41,356	$ 113	282,779	(241,536)
Beginning balance, Shares at Jun. 30, 2018		113,318,000
Issuance of common stock under employee and director stock option, RSU, and purchase plans	3	$ 0	3	0
Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares		205,000
Issuance of common stock from public offering, net	2,074	$ 2	2,072	0
Issuance of common stock from public offering, Shares		1,677,000
Stock-based compensation expense	1,274	$ 0	1,274	0
Net loss	(5,837)	0	0	(5,837)
Ending balance at Sep. 30, 2018	38,870	$ 115	286,128	(247,373)
Ending balance, Shares at Sep. 30, 2018		115,200,000
Stock option exercises	50	$ 1	49	0
Stock option exercises, Shares		622,000
Issuance of common stock under employee and director stock option, RSU, and purchase plans	(36)	$ 0	(36)	0
Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares		149,000
Issuance of common stock from public offering, net	1,832	$ 2	1,830	0
Issuance of common stock from public offering, Shares		1,799,000
Stock-based compensation expense	1,358	$ 0	1,358	0
Net loss	(6,399)	0	0	(6,399)
Ending balance at Dec. 31, 2018	35,675	$ 118	289,329	(253,772)
Ending balance, Shares at Dec. 31, 2018		117,770,000
Beginning balance at Mar. 31, 2019	36,298	$ 124	296,929	(260,755)
Beginning balance, Shares at Mar. 31, 2019		124,015,000
Issuance of common stock under employee and director stock option, RSU, and purchase plans	(52)	$ 0	(52)	0
Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares		177,000
Issuance of common stock from public offering, net	4,996	$ 6	4,990	0
Issuance of common stock from public offering, Shares		6,087,000
Stock-based compensation expense	1,220	$ 0	1,220	0
Net loss	(6,323)	0	0	(6,323)
Ending balance at Jun. 30, 2019	36,139	$ 130	303,087	(267,078)
Ending balance, Shares at Jun. 30, 2019		130,279,000
Beginning balance at Mar. 31, 2019	$ 36,298	$ 124	296,929	(260,755)
Beginning balance, Shares at Mar. 31, 2019		124,015,000
Stock option exercises, Shares	0
Net loss	$ (15,987)
Ending balance at Dec. 31, 2019	28,954	$ 130	305,566	(276,742)
Ending balance, Shares at Dec. 31, 2019		130,498,000
Beginning balance at Jun. 30, 2019	36,139	$ 130	303,087	(267,078)
Beginning balance, Shares at Jun. 30, 2019		130,279,000
Issuance of common stock under employee and director stock option, RSU, and purchase plans	(8)	$ 0	(8)	0
Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares		156,000
Stock-based compensation expense	1,236	$ 0	1,236	0
Net loss	(6,294)	0	0	(6,294)
Ending balance at Sep. 30, 2019	31,073	$ 130	304,315	(273,372)
Ending balance, Shares at Sep. 30, 2019		130,435,000
Issuance of common stock under employee and director stock option, RSU, and purchase plans	(1)	$ 0	(1)	0
Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares		63,000
Stock-based compensation expense	1,252	$ 0	1,252	0
Net loss	(3,370)	0	0	(3,370)
Ending balance at Dec. 31, 2019	$ 28,954	$ 130	$ 305,566	$ (276,742)
Ending balance, Shares at Dec. 31, 2019		130,498,000

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash Flows From Operating Activities
Net loss	$ (15,987)	$ (19,652)
Adjustments to reconcile net loss to net cash used in operating activities:
(Gain) loss on disposal of fixed assets	(111)	63
Gain on lease termination	(525)	0
Depreciation and amortization	1,136	824
Stock-based compensation	3,708	3,911
Inventory write-off	214	0
Increase (decrease) in cash resulting from changes in:
Accounts receivable	349	336
Grants receivable	55	21
Inventory	276	(207)
Prepaid expenses and other assets	654	637
Accounts payable	194	183
Accrued expenses	(1,013)	(1,185)
Deferred revenue	(525)	(107)
Deferred rent	0	(122)
Operating lease right-of-use assets and liabilities, net	(98)	0
Net cash used in operating activities	(11,673)	(15,298)
Cash Flows From Investing Activities
Purchases of fixed assets	0	(37)
Proceeds from disposals of fixed assets	728	3
Net cash provided by (used in) investing activities	728	(34)
Cash Flows From Financing Activities
Proceeds from issuance of common stock and exercise of warrants, net	4,996	6,916
Employee taxes paid related to net share settlement of equity awards	(61)	(136)
Proceeds from exercise of stock options	0	50
Net cash provided by financing activities	4,935	6,830
Net decrease in cash, cash equivalents, and restricted cash	(6,010)	(8,502)
Cash, cash equivalents, and restricted cash at beginning of period	36,556	43,853
Cash, cash equivalents, and restricted cash at end of period	30,546	35,351
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	30,467	35,224
Restricted cash	79	127
Cash, cash equivalents, and restricted cash at end of period	30,546	35,351
Supplemental Disclosure of Cash Flow Information:
Receivable related to fixed asset sales	11	0
Tenant improvements funded by landlord	37	0
Assets held for sale	38	0
Income taxes paid	$ 2	$ 3

Description of Business

Description of Business	9 Months Ended
	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business	Note Nature of operations Organovo Holdings, Inc. (“Organovo Holdings,” “we,” “us,” “our,” “the Company” and “our Company”) is a biotechnology company that has focused on pioneering the development of bioprinted human tissues that emulate human biology and disease. In August 2019, after a rigorous assessment of the Company’s lead liver therapeutic tissue program following completion of various preclinical studies, the Company’s Board of Directors (the “Board”) concluded that the variability of biological performance and related duration of potential benefits presented development challenges and lengthy redevelopment timelines that no longer supported an attractive opportunity for the Company and its stockholders. Furthermore, the Board deemed the stage of development of the Company’s other therapeutic pipeline assets, including stem cell based tissue programs, to be too premature to potentially reach IND filing status within an acceptable investment horizon and with the Company’s available resources. As a result, the Company suspended all development of its lead program and all other related pipeline development activity and engaged a financial advisory firm to explore its strategic alternatives, including a range of ways to generate value from the Company’s technology platform and intellectual property, its commercial and development capabilities, its listing on the Nasdaq Capital Market, and its remaining financial assets. On December 13, 2019, the Company and Tarveda Therapeutics, Inc. (“Tarveda”), a privately owned biopharmaceutical company, entered into an Agreement and Plan of Merger and Reorganization, as amended by the First Amendment to Merger Agreement, dated January 26, 2020, and as may be amended from time to time (the “Merger Agreement”). The Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Merger Agreement, Opal Merger Sub, Inc. (“Opal”), a new wholly-owned subsidiary of the Company, will merge with and into Tarveda, with Tarveda as the surviving corporation, becoming a wholly-owned subsidiary of the Company (the “Merger”). As a result of the Merger, each outstanding share of Tarveda capital stock will be converted into the right to receive shares of the Company’s common stock. Under the terms of the Merger Agreement, the Company will issue, and Tarveda securityholders will be entitled to receive, in a tax-free exchange, shares of its common stock such that Tarveda securityholders will own approximately 75% of the combined company on a fully diluted basis (as defined in the Merger Agreement) and the Company’s securityholders will own approximately 25% of the combined company on a fully diluted basis (as defined in the Merger Agreement). The Merger Agreement provides that the exchange ratio for Tarveda’s capital stock are subject to upward and downward adjustment based on the Company’s net cash balance at the closing of the Merger. If the Company’s net cash balance at the closing of the Merger is below $22 million, the Merger Agreement provides for adjusting the exchange ratio to increase the number of shares of its common stock issued to former Tarveda securityholders. As a result, Tarveda’s securityholders may receive additional shares of the Company’s common stock as Merger consideration, and consequently the Company’s securityholders may be further diluted as a result of the Merger. If the Company’s net cash balance at the closing of the Merger is above $22 million, the Merger Agreement provides for adjusting the conversion ratio to decrease the number of shares of its common stock issued to former Tarveda securityholders. Additionally, the Merger Agreement provides for certain adjustments for debt of each of the parties. These percentages are calculated based on other assumptions as well, and, to the extent these assumptions prove to be inaccurate, Tarveda’s securityholders may receive a larger or smaller percentage of the combined company’s pro forma fully diluted capitalization. If Tarveda’s net cash balance at the closing of the Merger is below $15 million, the Company may elect to not consummate the Merger. The Merger is subject to customary closing conditions, including approval by the Company’s stockholders of the issuance of its common stock in the Merger, as well as a reverse stock split of its common shares. The Company anticipates the Merger will be completed in the fiscal fourth quarter of 2020. The Merger Agreement contains certain termination rights for both the Company and Tarveda, and further provides that, upon termination of the Merger Agreement under specified circumstances, either party may be required to pay the other party a termination fee ranging between $1.0 million (plus reimbursement of $0.3 million of expenses) and $2.0 million (plus reimbursement of $0.5 million of expenses), depending on the cause of the termination. Prior to execution of the Merger Agreement, the Company solicited bids from potential purchasers for its operating assets, which the Company had sought to sell or otherwise dispose of in one or more strategic transactions. In connection with that process, the Company entered into an agreement with LifeNet Health (“LifeNet”) on November 7, 2019 to sell certain equipment and inventory of our Samsara Sciences, for $1.5 million in cash. In addition, on January 26, 2020, the Company and Tarveda agreed to amend the Merger Agreement to provide that the Company would be credited with $1.5 million for purposes of calculating the number of shares to be issued to Tarveda stockholders in connection with the Merger if the Company does not sell or transfer its intellectual property and remaining assets prior to the closing of the Merger. The Company’s remaining assets following these actions will consist primarily of its cash, cash equivalents, interest receivables, restricted cash and other working capital items related to its corporate administrative function, its intellectual property portfolio, its license and collaboration agreements, its remaining assets, its listing on the Nasdaq Capital Market and the Merger Agreement with Tarveda. In addition, the majority of the Company’s employees have been terminated, except for six general and administrative personnel. As a result of the sale transaction with LifeNet, aside from the maintenance of the Company’s intellectual property portfolio, license and collaboration agreements, its remaining assets, and its listing on the Nasdaq Capital Market, all of the Company’s business immediately following the Merger will be the business conducted by Tarveda immediately prior to the Merger, if the Merger closes. Accordingly, because of the pending Merger with Tarveda and the action described above, the Company believes its historical operating results are not indicative of future results. The Company cannot assure you that it will close the pending Merger with Tarveda on favorable terms, in a timely manner, or at all. Except where specifically noted or the context otherwise requires, references to “Organovo Holdings,” “the Company,” “we,” “our,” and “us” in these notes to the unaudited condensed consolidated financial statements refers to Organovo Holdings, Inc. and its wholly owned subsidiaries, Organovo, Inc., Samsara Sciences, Inc, and Opal Merger Sub, Inc.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not necessarily include all information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet at March 31, 2019 is derived from the Company’s audited consolidated balance sheet at that date. The unaudited condensed consolidated financial statements include the accounts of Organovo Holdings and its wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Company’s financial position, results of operations, stockholders’ equity and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2019, as filed with the Securities and Exchange Commission (“SEC”). Operating results for interim periods are not necessarily indicative of operating results for the Company’s fiscal year ending March 31, 2020 (see “ Note 1. Description of Business” Liquidity As of December 31, 2019, the Company had cash and cash equivalents of approximately $30.5 million and restricted cash of approximately $0.1 million. The restricted cash was pledged as collateral for a letter of credit that the Company is required to maintain as a security deposit under the terms of the lease of its facilities. The Company had an accumulated deficit of approximately $276.7 million at December 31, 2019. The Company also had negative cash flows from operations of approximately $11.7 million during the nine months ended December 31, 2019. Through December 31, 2019, the Company has financed its operations primarily through the sale of convertible notes, warrants, the private placement of equity securities, the sale of common stock through public and at-the-market (“ATM”) offerings, and through revenue derived from product and research service-based agreements, collaborative agreements, licenses, and grants. During the three and nine months ended December 31, 2019, the Company issued 0 and 6,087,382 shares of its common stock through its ATM facility and received net proceeds of approximately $0 and $5.0 million, respectively. Throughout the strategic alternatives assessment process, the Company has taken steps to manage its resources and extend its cash runway including reducing commercial activities related to its liver tissues, except for sales of primary human cells out of inventory, negotiating an exit from its long-term facility lease, selling various assets, and reducing its workforce to the minimum level necessary to As a result, the Company terminated the employment of 52 employees, or 90% of its workforce and recorded a restructuring charge during the nine months ended December 31, 2019 of approximately $2.8 million, primarily related to employee severance and benefits costs, of which $1.7 million was paid out during the fiscal second quarter, $0.9 million was paid out during the fiscal third quarter, and the remainder is anticipated to be paid out during the fiscal fourth quarter. The Company currently expects further restructuring actions tied to the completion of the Merger with Tarveda, which could lead to an additional $3.5 million of severance and benefits costs that would The Company’s expenses may exceed its current plans and expectations, and, if the Merger with Tarveda is not completed, it could cause the Company to complete another transaction or wind-down its operations sooner than anticipated. If the Company is unable to successfully complete the Merger with Tarveda or another strategic transaction or secure additional capital on a timely basis and on terms that are acceptable to its stockholders, the Company may elect to cease its operations altogether, in which event the value realized by its stockholders might be significantly less than the $29.0 million of stockholders’ equity recorded on the Company’s consolidated financial statements as of December 31, 2019. While the Company believes that it can maintain its current operations for at least the next 12 months, based on its current plans and available resources, the assessment by the Company discussed above with respect to the Merger with Tarveda and other alternatives raises substantial doubt over the Company’s ability to successfully finance itself on a long-term basis. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Use of estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates used in preparing the condensed consolidated financial statements include those assumed in revenue recognition, the measurement of operating lease right-of-use assets and lease liabilities, the valuation of stock-based compensation expense, the valuation of impairment of long-lived assets, and the valuation allowance on deferred tax assets. On an ongoing basis, management reviews these estimates and assumptions. Impairment of long-lived assets In accordance with ASC 360-10, the Company records an impairment loss on long-lived assets used in operations when events and circumstances indicate that long-lived assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets (i.e. not able to be recovered). During the second quarter of Fiscal 2020, the Company announced the restructuring of its operations. This event required the reevaluation of the recoverability of the gross carrying value of its long-lived assets. Upon the Company’s announcement and at each quarter-end, the Company performed an asset impairment analysis on its long-lived asset group, consisting primarily of licensed intangible assets, computer equipment, and software following the completion of various asset sales prior to December 31, 2019, which concluded that the carrying amount is not recoverable. However, the Company’s analysis indicated that carrying amount of the asset group does not exceed its fair value. As such, no impairment loss is required to be recognized. Nonetheless, it is reasonably possible that the impairment analysis may change in the near term resulting in the need to write down those assets to fair value. The Company will continue to monitor assets for impairment. Revenue recognition The Company has generated revenues from payments received from research service agreements, product sales, collaborative agreements with partners including pharmaceutical and biotechnology companies and academic institutions, licenses, and grants from the National Institutes of Health (“NIH”) and private not-for-profit organizations. The Company recognizes revenue under Topic 606, Revenue from Contracts with Customers Billings to customers or payments received from customers are included in deferred revenue on the balance sheet until all revenue recognition criteria are met. As of December 31, 2019 and March 31, 2019, the Company had approximately $0 and $525,000, respectively, in deferred revenue related to its research service agreements, collaborative agreements, and licenses within the scope of Topic 606. In the nine months ended December 31, 2019, the Company recognized revenue on approximately $525,000, of which $490,000 related to the expiration of an agreement with a non-refundable up-front fee, that had been recorded as deferred revenue at March 31, 2019. Service revenues The Company’s service-based business, Organovo, Inc., utilized its NovoGen® bioprinting platform to provide customers access to its highly specialized tissues that model human biology and disease, and to in vitro For service contracts, the Company allocated the transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. If the standalone selling price was not observable through past transactions, the Company estimated the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The transaction price for service business contracts was a fixed consideration. In connection to the Company’s decision to pursue its strategic alternatives, the Company reduced commercial activities related to its liver tissues, except for sales of primary human cells out of inventory. The Company is expected to continue to maintain its external research collaborations and its intellectual property portfolio through the closing of the Merger. Product sales, net The Company’s product-based business, Samsara Sciences, Inc., produced high-quality cell-based products for use in Organovo’s 3D tissue manufacturing and for use by life science customers. The Company recognizes product revenue when the performance obligation is satisfied, which is at the point in time the customer obtains control of the Company’s product, typically upon delivery. Product revenues are recorded at the transaction price, net of any estimates for variable consideration under Topic 606. The Company’s process for estimating variable consideration does not differ materially from its historical practices. Variable consideration is estimated using the expected value method which considers the sum of probability-weighted amounts in a range of possible amounts under the contract. Product revenue reflects the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the individual contracts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. The Company provides no right of return to its customers except in cases where a customer obtains authorization from the Company for the return. To date, there have been no product returns. The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and adjusts its estimates accordingly. On November 7, 2019, the Company entered into an agreement to sell substantially all of the Samsara inventory and associated assets for $1.5 million, which was recorded to other income. As a result, the Company will have no further product sales of cells nor tissues beyond what it sold prior to the November 7 th Collaborative research, development, and licenses The Company has entered into collaborative agreements with partners that typically include one or more of the following: (i) non-exclusive license fees; (ii) non-refundable up-front fees; (iii) payments for reimbursement of research costs; (iv) payments associated with achieving specific development milestones; and (v) royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company has analyzed whether it results in a contract with a customer under Topic 606 or in an arrangement with a collaborator subject to guidance under ASC 808, Collaborative Arrangements The Company has considered a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements are distinct performance obligations, whether there are determinable stand-alone prices, and whether any licenses are functional or symbolic. The Company has evaluated each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, non-exclusive license fees, non-refundable upfront fees, and funding of research activities have been considered fixed, while milestone payments have been identified as variable consideration which must be evaluated to determine if it has been constrained and, therefore, excluded from the transaction price. The Company’s collaborative agreements that were not completed at the implementation of Topic 606 on April 1, 2018, consisted of research collaboration and limited technology access licenses. These agreements provide the licensee with a non-exclusive, non-transferable, limited, royalty-free technology license, including access to Organovo’s proprietary bioprinter platform, training, and continued support by means of consumables and consultation throughout the duration of the contract. The Company has determined that the intellectual property license is not distinct from the continued support promised under the agreement and is therefore a single combined performance obligation. The Company recognized revenue for these combined performance obligations over time for the duration of the license period, as the combined performance obligation would not be fully satisfied until the end of the contract. For the nine months ended December 31, 2019, all collaborations and licenses revenue was within the scope of Topic 606 and recognized accordingly. As of September 30, 2019, the Company completed its obligations under the existing agreements with respect to receipts of revenue and does not anticipate recording any further revenue. Grant revenue In July 2017, the NIH awarded the Company a “Research and Development” grant totaling approximately $1,657,000 of funding over three years. The Company has concluded this government grant is not within the scope of Topic 606, as government entities do not meet the definition of a “customer” as defined by Topic 606, as there is not considered to be a transfer of control of goods or services to the government entity funding the grant. Additionally, the Company has concluded this government grant does meet the definition of a contribution and is a non-reciprocal transaction, however, Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition does not apply, as the Company is a business entity and the grant is with a governmental agency. Revenues from this grant have been based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue has been recognized as the Company incurs expenses that are related to the grant. T he Company believes this policy is consistent with the overarching premise in Topic 606, to ensure that it recognizes revenues to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services, even though there is no “exchange” as defined in the ASC. The Company believes the recognition of revenue as costs are incurred and amounts become earned/realizable is analogous to the concept of transfer of control of a service over time under Topic 606. As of December 31, 2019, the Company has recognized approximately $1.2 million in grant revenue. Revenue recognized under this grant was approximately $0 and $52,000 for the three and nine months ended December 31, 2019, respectively. Revenue recognized under this grant was approximately $66,000 and $574,000 for the three and nine months ended December 31, 2018, respectively. In connection to the Company’s decision to pursue its strategic alternatives, specific to the NIH NASH grant, all internal research activities have been halted, leaving a remaining available balance of approximately $0.5 million that will not be utilized by the Company. Cost of revenues The Company reported approximately less than $0.1 million and $0.3 million in cost of revenues for the three and nine months ended December 31, 2019, respectively, which includes an inventory write-off during the fiscal second quarter of approximately $0.2 million consisting of raw materials related to the Company’s bioprinting and testing services and is a result of the Company’s decision to pursue its strategic alternatives. The Company reported approximately $0.1 million and $0.4 million in cost of revenues for the three and nine months ended December 31, 2018, respectively. Cost of revenues consists of costs related to manufacturing and delivering product and service revenue. Net loss per share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options and warrants, shares reserved for purchase under the Company’s 2016 Employee Stock Purchase Plan (“ESPP”), the assumed release of restriction of restricted stock units, and shares subject to repurchase as the effect would be anti-dilutive. No dilutive effect was calculated for the three and nine months ended December 31, 2019 or 2018, as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. Common stock equivalents excluded from computing diluted net loss per share were approximately 16.7 million at December 31, 2019 and 15.6 million at December 31, 2018. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption. Adoption of New Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases (“ASC 842”), which supersedes the lease guidance under ASC 840 – Leases. The new accounting standard requires an entity to recognize right-of-use assets and corresponding lease liabilities on the balance sheet for all leases with terms of more than 12 months and to disclose key information about leasing arrangements. This new guidance became effective for the Company on April 1, 2019. The Company adopted ASC 842 on April 1, 2019 and elected the optional transition method that allows for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior periods. The Company elected the package of practical expedients permitted under the transition guidance, but not the hindsight practical expedient. Please refer to “Note 6. Leases” for more information regarding the Company’s adoption of the new lease standard. In February 2018, the FASB issued ASU No. 2018-02, Income Statement – Reporting Comprehensive Income In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting Recent Accounting Pronouncements Not Yet Adopted In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Stockholders' Equity	Note 3. Stockholders’ Equity Stock-based compensation expense and valuation information Stock-based awards include stock options and restricted stock units under the 2012 Equity Incentive Plan, as amended (“2012 Plan”) and Inducement Awards, performance-based restricted stock units under an Incentive Award Performance-Based Restricted Stock Unit Agreement, and rights to purchase stock under the 2016 Employee Stock Purchase Plan (“ESPP”). The Company calculates the grant date fair value of all stock-based awards in determining the stock-based compensation expense. Stock-based compensation expense for all stock-based awards consists of the following (in thousands): Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended December 31, 2019 December 31, 2018 December 31, 2019 December 31, 2018 Research and development $ 66 $ 249 $ 240 $ 679 General and administrative $ 1,186 $ 1,109 $ 3,468 $ 3,232 Total $ 1,252 $ 1,358 $ 3,708 $ 3,911 The total unrecognized compensation cost related to unvested stock option grants as of December 31, 2019 was approximately $4,855,000 and the weighted average period over which these grants are expected to vest is 2.12 years. The total unrecognized compensation cost related to unvested restricted stock units (not including performance-based restricted stock units) as of December 31, 2019 was approximately $1,642,000, which will be recognized over a weighted average period of 1.97 years. The total unrecognized compensation cost related to unvested performance-based restricted stock units as of December 31, 2019 was approximately $2,339,000, which will be recognized over a weighted average period of 1.60 years. As of December 31, 2019, there are no participants enrolled into the employee stock purchase plan for the current purchase period, beginning September 1, 2019. The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions: Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended December 31, 2019 * December 31, 2018 December 31, 2019 December 31, 2018 Dividend yield — — — — Volatility 0.00 % 73.07 % 84.36 % 72.99 % Risk-free interest rate 0.00 % 2.79 % 1.53 % 2.75 % Expected life of options — 6.00 years 6.00 years 6.00 years Weighted average grant date fair value $ — $ 0.67 $ 0.23 $ 0.84 *No options were granted in the three months ended December 31, 2019. The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. Prior to fiscal year 2020, the Company used a blend of historical volatility and implied volatility of comparable companies. As of April 1, 2019, the Company is using the Company-specific historical volatility rate as it is more reflective of market conditions and a better indicator of expected volatility. The risk-free interest rate assumption was based on U.S. Treasury rates. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options. Prior to fiscal year 2020, certain options granted to consultants were subject to variable accounting treatment and were required to be revalued until vested. As of April 1, 2019, the measurement and classification of share-based payment to non-employees is consistent with the measurement and classification of share-based payment to employees. The fair value of each restricted stock unit and performance-based restricted stock unit is recognized as stock-based compensation expense over the vesting term of the award. The fair value is based on the closing stock price on the date of the grant. The Company uses the Black-Scholes valuation model to calculate the fair value of shares issued pursuant to the Company’s ESPP. Stock-based compensation expense is recognized over the purchase period using the straight-line method. The fair value of ESPP shares was estimated at the purchase period commencement date using the following assumptions: Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended December 31, 2019* December 31, 2018 December 31, 2019* December 31, 2018 Dividend yield — — — — Volatility 0.00 % 80.23 % 43.69 % 61.35 - 80.23% Risk-free interest rate 0.00 % 2.29 % 2.52 % 1.85 - 2.29% Expected term — 6 months 6 months 6 months Grant date fair value $ — $ 0.45 $0.29 $0.30 - $0.45 *There are no participants in the ESPP for the current purchase period (beginning September 1, 2019). The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. The Company uses the Company-specific historical volatility rate as the indicator of expected volatility. The risk-free interest rate assumption was based on U.S. Treasury rates. The expected life is the 6-month purchase period. Preferred stock The Company is authorized to issue 25,000,000 shares of preferred stock. There are no shares of preferred stock currently outstanding, and the Company has no current plans to issue shares of preferred stock. Common stock On June 25, 2019, the Company received a notice letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets the requirement to maintain a minimum closing bid price of $1 per share, as set forth in Nasdaq Listing Rule 5450(a)(1). On December 26, 2019, the Company obtained an additional compliance period of 180 calendar days by electing to transfer to The Nasdaq Capital Market. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market. In connection with the Merger with Tarveda, the Company is also seeking to effect a reverse stock split, which would be subject to the prior approval of the Company’s stockholders. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or maintain compliance with the other listing requirements necessary to maintain the listing of its common stock on the Nasdaq Capital Market. The Company’s failure to regain compliance during this second compliance period could result in delisting and impact our ability to complete the Merger with Tarveda. The Company has an effective shelf registration statement on Form S-3 (File No. 333-222929) and the related prospectus previously declared effective by the Securities and Exchange Commission (the “SEC”) on February 22, 2018 (the “2018 Shelf”), that expires on February 22, 2021, which registered $100,000,000 of common stock, preferred stock, warrants and units, or any combination of the foregoing. On March 16, 2018, the Company entered into a Sales Agreement (“2018 Sales Agreement”) with H.C. Wainwright & Co., LLC and Jones Trading Institutional Services LLC (each an “Agent” and together, the “Agents”) and filed a prospectus supplement to the 2018 Shelf, pursuant to which the Company may offer and sell, from time to time through the Agents, shares of its common stock in at-the-market sales transactions having an aggregate offering price of up to $50,000,000 (the “Shares”). Any shares offered and sold will be issued pursuant to the Company’s 2018 Shelf. During the three and nine months ended December 31, 2019, the Company issued 0 and 6,087,382 shares of common stock, respectively, for net proceeds of $0 and $5.0 million in at-the-market offerings under the 2018 Sales Agreement. During the three and nine months ended December 31, 2018, the Company issued 1,798,384 and 5,560,514 shares of common stock, respectively, for net proceeds of approximately $1.9 million and $6.9 million under the 2018 Sales Agreement. As of December 31, 2019, the Company has sold an aggregate of 17,719,185 shares of common stock in at-the-market offerings under the 2018 Sales Agreement, with gross proceeds of approximately $18.7 million. Based on these sales, the Company cannot raise more than an aggregate of $81.3 million in future offerings under the 2018 Shelf, including the $31.3 million remaining available for future issuance through its at-the-market program under the 2018 Sales Agreement. On July 26, 2018, the Company filed an amendment to its certificate of incorporation to increase the number of authorized shares of common stock to 200,000,000 shares. Restricted stock units A summary of the Company’s restricted stock units (not including performance-based restricted stock units) activity from March 31, 2019 through December 31, 2019 is as follows: Number of Shares Weighted Average Price Unvested at March 31, 2019 2,080,723 $ 1.80 Granted 585,926 $ 0.97 Vested (500,666 ) $ 2.26 Cancelled / forfeited (1,057,673 ) $ 1.23 Unvested at December 31, 2019 1,108,310 $ 1.70 Performance-based restricted stock units On April 24, 2017, the Company issued a Performance-Based Restricted Stock Unit Award for 208,822 shares of common stock (the “PBRSU”) to its newly hired Chief Executive Officer. The PBRSU was issued outside of the 2012 Plan, in the Inducement Award Agreement, as an “inducement award” within the meaning of Nasdaq Marketplace Rule 5635(c)(4). While outside the Company’s 2012 Plan, the terms and conditions of these awards are consistent with awards granted to the Company’s executive officers pursuant to the 2012 Plan. On August 23, 2017, the Board of Directors formally approved the vesting criteria for the PBRSU. The vesting of the PBRSU is divided into five separate tranches each with independent vesting criteria. The first four tranches had performance criteria related to annual revenue goals with measurement at the end of fiscal year 2018 (20 percent), fiscal year 2019 (20 percent), fiscal year 2020 (20 percent), and fiscal year 2021 (20 percent). The fifth tranche had a performance metric related to a path to profitability goal measured as Negative Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) achievable at any point between the grant date and the end of fiscal year 2020 (20 percent). The number of units that ultimately vest for each tranche will range from 0 percent to 120 percent of the target amount, not to exceed 208,822 in aggregate. On December 12, 2018, the Board of Directors formally approved an amendment to the vesting criteria for the PBRSUs. As of December 12, 2018, 100% of the Negative Adjusted EBITDA tranche, or 41,764 shares had vested and 8,352 units had been forfeited. Based on the amendment to the vesting criteria, the remaining 158,706 units eligible to vest upon future performance were divided into three separate but equal tranches with independent vesting criteria based on the achievement of certain regulatory milestones. As of December 31, 2019, no tranches are expected to vest unless there is a change in control. Based on the amended PBRSU vesting terms, a Type III modification, the modified grant date fair value of the PBRSUs is $165,000 of which one-third is being recognized over the expected service period of each tranche ending on April 23, 2023. The Company began recording stock-based compensation expense for the initial performance tranches after the August 23, 2017 grant date when the initial financial performance goals were established and approved and has modified its recording of compensation expense in accordance with the amended performance tranches beginning on December 12, 2018. On July 2, 2019, the Company issued Performance-Based Restricted Stock Unit Awards (the “PBRSU Retention Awards”) for an aggregate of 6,027,899 shares of common stock to its management team. The PBRSUs were issued pursuant to the 2012 Plan. The PBRSU Retention Awards will vest in full upon the earlier of the Company’s engagement in a pre-IND meeting with the FDA, twenty-four months from the grant date, or a change in control. As of December 31, 2019, all PBRSUs are expected to vest twenty-four months from the grant date. A summary of the Company’s performance-based restricted stock unit activity from March 31, 2019 through December 31, 2019 is as follows: Number of Shares Weighted Average Price Unvested at March 31, 2019 158,706 $ 1.04 Granted 6,027,899 $ 0.49 Vested — $ — Cancelled / forfeited — $ — Unvested at December 31, 2019 6,186,605 $ 0.50 Stock options A summary of the Company’s stock option activity from March 31, 2019 to December 31, 2019 is as follows: Options Outstanding Weighted Average Exercise Price Aggregate Intrinsic Value Outstanding at March 31, 2019 12,039,264 $ 2.24 $ — Options granted 342,500 $ 0.32 $ — Options cancelled / forfeited (3,015,090 ) $ 2.68 $ — Options exercised — $ — $ — Outstanding at December 31, 2019 9,366,674 $ 2.02 $ 23,322 Vested and Exercisable at December 31, 2019 4,019,674 $ 2.73 $ — The weighted average remaining contractual term of options exercisable and outstanding at December 31, 2019 was approximately 7.23 years. Employee Stock Purchase Plan In June 2016, Warrants The following table summarizes warrant activity for the nine months ended December 31, 2019: Warrants Weighted Average Exercise Price Balance at March 31, 2019 145,000 $ 7.11 Granted — $ — Exercised — $ — Cancelled (145,000 ) $ 7.11 Balance at December 31, 2019 — $ — There are no warrants outstanding as of December 31, 2019. Common stock reserved for future issuance Common stock reserved for future issuance consisted of the following at December 31, 2019: Common stock options outstanding and reserved under the 2012 Plan 6,547,442 Common stock reserved under the 2012 Plan 10,482,484 Common stock reserved under the 2016 Employee Stock Purchase Plan 1,188,718 Restricted stock units outstanding under the 2012 Plan 987,775 Performance-based restricted stock units outstanding under the 2012 Plan 6,027,899 Common stock options outstanding and reserved under the Incentive Award Agreement 2,819,232 Restricted stock units outstanding under the Incentive Award Agreement 120,535 Performance-based restricted stock units outstanding under the Incentive Award Agreement 158,706 Total at December 31, 2019 28,332,791

Collaborative Research, Develop

Collaborative Research, Development, and License Agreements	9 Months Ended
	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaborative Research, Development, and License Agreements	Note 4. Collaborative Research, Development, and License Agreements In December 2016, the Company signed a collaborative non-exclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen® Bioprinter at the university for the purpose of developing a kidney organoid for potential therapeutic applications. The Company received up-front payments in January and March 2017, which has been recorded as deferred revenue. Revenue of $0 and $19,000 was recorded under this agreement for the three and nine months ended December 31, 2019, respectively. Revenue of $10,000 and $29,000 was recorded under this agreement for the three and nine months ended December 31, 2018, respectively. The Company completed its obligations under this agreement and does not anticipate recording any further revenue. In April 2017, the Company signed a collaborative non-exclusive research affiliation with a university, under which the Company received a one-time non-refundable payment toward the placement of a NovoGen® Bioprinter at the university for the purpose of specific research projects mutually agreed upon by the university and the Company in the field of volumetric muscle loss. The Company received an up-front payment in May 2017, which was recorded as deferred revenue. No revenue has been recorded under this agreement for the three and nine months ended December 31, 2019. ely $14,000 and $43,000 has been recorded under this agreement for the three and nine months ended December 31, 2018, respectively. In addition, during April 2017, the Company signed a non-exclusive patent license agreement with the university including an annual fee of $75,000 for each of the two years for the license to the Company patents for research use limited to the field of volumetric muscle loss. The Company received the first annual payment of $75,000 in April 2017 and the second annual payment of $75,000 in May 2018, which were initially recorded as deferred revenue. No revenue has been recorded under this agreement for the three and nine months ended December 31, 2019. Revenue of $18,000 and $56,000 was recorded under this agreement for the three and nine months ended December 31, 2018, respectively.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 5. Commitments and Contingencies Legal matters In addition to commitments and obligations in the ordinary course of business, the Company may be subject, from time to time, to various claims and pending and potential legal actions arising out of the normal conduct of its business. On October 10, 2019, a putative class action lawsuit was filed in the U.S. District Court for the District of Delaware against the Company and its board of directors in connection with the annual proxy statement filed by the Company on July 26, 2019. The case is captioned Rianhard v. Crouch., et al., Case No. 19-cv-1922 (D. Del. Oct. 10, 2019) (the “Action”). The complaint alleged that the Schedule 14A proxy statement contained material misrepresentations in connection with the reverse stock split proposal recommended therein and asserted claims for violations of Section 14(a) of the Securities Exchange Act of 1934 and Rule 14a-9 promulgated thereunder, as well as claims for breach of fiduciary duty. On November 25, 2019, the Action was voluntarily dismissed. On December 31, 2019, the Company received a demand pursuant to Delaware General Corporation Law Section 220 for certain books and records of the Company (the “Demand”). The Company has objected to the Demand and is in discussions with the demanding stockholder to provide certain records. On January 30, 2020, the Company received a demand letter (the “Letter”) from a purported stockholder alleging that the disclosures in the Form S-4 filed with the SEC on December 23, 2019 violated federal securities laws by failing to disclose certain allegedly material information. The Letter demands, among other things, that the Company make corrective disclosures and reserves the right to pursue legal action. The Company believes the assertions in the Letter are without merit. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing litigation contingencies is subjective and requires judgments about future events. When evaluating contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed in litigation against it may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of its potential liability. The Company regularly reviews contingencies to determine the adequacy of its accruals and related disclosures. During the period presented, the Company has not recorded any accrual for loss contingencies associated with any claims or legal proceedings; determined that an unfavorable outcome is probable or reasonably possible; or determined that the amount or range of any possible loss is reasonably estimable. However, the outcome of legal proceedings and claims brought against the Company is subject to significant uncertainty. Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against the Company in a reporting period, the Company’s consolidated financial statements for that reporting period could be materially adversely affected.

Leases

Leases	9 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Leases	Note 6. Leases Adoption of ASC 842 As of April 1, 2019, the Company adopted ASC 842, which requires lessees to recognize a right-of-use asset (ROU asset) and lease liability for leases with terms of greater than twelve months. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company implemented this new accounting standard using the modified retrospective method for its existing leases, which did not cause any adjustments to prior year financial statements. The Company elected the package of practical expedients available for existing contracts, which allowed it to carry forward its historical assessments of whether contracts are or contain leases and the classification of its existing operating leases. Additionally, the Company elected the practical expedient to treat lease and non-lease components as a single lease component. At the time of adoption, the Company leased property and equipment under operating leases, specifically its office building and various copier machines. The Company also had a short-term lease (lease term is less than 12 months), which is not required to be recorded on the balance sheet under ASC 842. Instead, under ASC 842, the Company elected the accounting policy for short term leases to recognize lease payments as an expense on a straight-line basis over the lease term. Upon adoption of ASC 842, the Company recognized ROU assets and corresponding lease liabilities based on the present value of remaining lease payments over the lease terms. ROU assets were measured as lease liabilities plus prepaid rent less any deferred rent. As interest rates were not implicitly stated in the respective lease agreements, nor were they readily determinable, the Company used its incremental borrowing rate as the discount rate when measuring lease liabilities. As a result, the Company recorded ROU assets and lease liabilities of $4.5 million and $5.0 million, respectively. The Company also classified deferred rent of $0.6 million as an offset to the Company’s ROU asset upon adoption. The impact of the adoption of ASC 842 on the consolidated balance sheet as of April 1, 2019 is as follows (in thousands): ASC 840 ASC 842 March 31, 2019 Impact of Adoption April 1, 2019 Deferred Rent $ 35 $ (35 ) $ — Deferred Rent, net of current portion $ 588 $ (588 ) $ — Prepaid Rent $ 88 $ (88 ) $ — Operating right-of-use assets $ — $ 4,451 $ 4,451 Operating lease liability $ — $ 1,038 $ 1,038 Operating lease liability, net of current portion $ — $ 3,948 $ 3,948 After the initial adoption of ASC 842, on an on-going basis, the Company evaluates all contracts upon inception and determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of identified asset in exchange for consideration over a period of time. If a lease is identified, the Company will apply the guidance from ASC 842 to properly account for the lease. Operating Leases From July 2012 to November 2019, the Company leased its main facilities at 6275 Nancy Ridge Drive, San Diego, California 92121. The lease, as amended in 2013, 2015, 2016, 2018, and 2019, consisted of approximately 45,580 rentable square feet containing laboratory, clean room and office space. Monthly rental payments are approximately $87,000 with 3% annual escalators. The lease for 14,685 of the total rentable square footage was amended to accelerate the expiration date from December 15, 2018 to October 31, 2018. On November 30, 2018, the Company agreed to extend the term for the remainder of the total rentable square footage under the lease from August 31, 2021 to August 31, 2024 in exchange for $500,000 of landlord funded tenant improvements and a rescission of its option to terminate the lease on or after September 1, 2019 with 9 months prior written notice. On October 11, 2019, the Company entered into an agreement to accelerate the expiration date of the term of the lease for its main facilities on 6275 Nancy Ridge Drive from August 31, 2024 to November 15, 2019. Under this agreement, the Landlord and Tenant agreed that the other is excused as of the termination date from any further obligations. As such, the Company wrote-off its associated right-of-use asset of approximately $4.1 million and lease liabilities of approximately $4.6 million in the third quarter of Fiscal 2020, which resulted in a $0.5 million gain on lease termination. In addition to the Company’s main facility lease, on March 21, 2019, the Company entered into an agreement to lease several copy machines for a term of 36 months. The lease contained fixed monthly payments through the entire term of the lease, and it did not contain an option to extend the term or a bargain purchase option. This lease was also carried forward as an operating lease through the adoption of Topic 842. On October 9, 2019, the Company entered into an agreement to assume its leased copy machines, which terminates future obligations. As such, the Company wrote-off its associated right-of-use asset of approximately $26,000 and lease liabilities of approximately $26,000 in the third quarter of Fiscal 2020. On October 2, 2019, the Company entered into an agreement to rent office space at 440 Stevens Avenue, Suite 200, Solana Beach, California 92075. This agreement is a month-to-month contract and can be terminated at-will by either party at any time. As such, the Company has concluded that this agreement does not contain a lease and will be expensed as incurred. Monthly rental payments are approximately $4,000 per month. The Company recorded operating lease expense on a straight-line basis over the life of the leases. This is consistent with the Company’s historical treatment of the lease costs included in operating expenses (referred to as “Rent Expense” prior to adoption of Topic 842). For the three and nine months ended December 31, 2019, the Company recorded operating lease expense of approximately $45,000 and $568,000, respectively. In addition, the Company recorded rent expense for the office space of approximately $7,000 for the three and nine months ended December 31, 2019. For the three and nine months ended December 31, 2018, the Company recorded rent expense of approximately $264,000 and $915,000, respectively. Variable lease costs associated with the Company’s leases, such as payments for additional monthly fees to cover the Company’s share of certain facility expenses (common area maintenance, or CAM) are not included in operating lease right-of-use assets and lease liabilities, but rather expensed as incurred. Variable lease expense was approximately $65,000 and $302,000 for the three and nine months ended December 31, 2019, respectively. Short-term lease cost for the three and nine months ended December 31, 2019 was approximately $0 and $37,000, respectively. The short-term lease was terminated in the fiscal second quarter. The table below is a summary of the cash flows associated with the Company’s leases for the nine months ended December 31, 2019 (in thousands): For the Nine Months Ended December 31, 2019 Cash paid for amount included in measurement of liabilities: Operating cash flows from operating leases $ 579

Concentrations

Concentrations	9 Months Ended
	Dec. 31, 2019
Risks And Uncertainties [Abstract]
Concentrations	Note 7. Concentrations Credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. The Company maintains cash balances at various financial institutions located within the United States. Accounts at these institutions are secured by the Federal Deposit Insurance Corporation. Balances may exceed federally insured limits. The Company has not experienced losses in such accounts and management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents. The Company is also potentially subject to concentrations of credit risk in its revenues and accounts receivable. Because it is in the early commercial stage, the Company’s revenues to date have been derived from a relatively small number of customers and collaborators. However, the Company has not historically experienced any accounts receivable write-downs and management does not believe significant credit risk exists as of December 31, 2019.

Related Parties

Related Parties	9 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Parties	Note 8. Related Parties From time to time, the Company will enter into an agreement with a related party in the ordinary course of its business and on terms and conditions it believes are as fair as those it offers and receives from independent third parties. These agreements are ratified by the Company’s Board of Directors or a committee thereof pursuant to its related party transaction policy. In August 2017, the Company entered into a research services agreement with Cirius Therapeutics, Inc. (“Cirius”), an entity for which Robert Baltera, Jr., a former director of the Company, serves as Chief Executive Officer and President. Under this agreement, the Company is providing standard research services to Cirius utilizing its ExVive™ Liver Tissue platform. The Company has provided and recognized revenue for ExVive™ Liver Tissue Services for Cirius in the amount of $281,000 to date. Organovo completed its obligations as of December 2018. No further revenues are expected. In November 2018, the Company entered into a research services Quote with Viscient Biosciences (“Viscient”), an entity for which Keith Murphy, the Company’s former director, Chief Executive Officer, and President, serves as the Chief Executive Officer and President. Under this Quote, the Company is providing research services in the amount of $142,000, amended in April 2019 to include an additional $7,000 of services. As of March 31, 2019, the Company recognized revenue of $42,000 for services provided and the remaining amount of $107,000 was recognized as revenue in the nine months ended December 31, 2019. In November 2019, the Company entered into an agreement with Viscient to sell certain bioprinting equipment and a non-exclusive license to certain intellectual property for approximately $171,000, of which $101,000 was recognized as other income and $70,000 was recognized as revenue in the nine months ended December 31, 2019. In addition to the services provided by Organovo, Viscient has purchased primary human cell-based products from our subsidiary, Samsara. Pursuant to the terms of multiple Quotes, $44,000 and $128,000 was recognized as revenue in the three and nine months ended December 31, 2019, respectively. Pursuant to the terms of multiple Quotes, $88,000 and $91,000 was recognized as revenue in the three and nine months ended December 31, 2018, respectively.

Restructuring

Restructuring	9 Months Ended
	Dec. 31, 2019
Restructuring And Related Activities [Abstract]
Restructuring	Note 9. Restructuring In August 2019, after a rigorous assessment of the Company’s lead liver therapeutic tissue program following completion of various preclinical studies, the Company’s Board of Directors (the “Board”) concluded that the variability of biological performance and related duration of potential benefits presented development challenges and lengthy redevelopment timelines that no longer supported an attractive opportunity for the Company and its stockholders. Furthermore, the Board deemed the stage of development of the Company’s other therapeutic pipeline assets, including stem cell based tissue programs, to be too premature to potentially reach IND filing status within an acceptable investment horizon and with the Company’s available resources. As a result, the Company suspended all development of its lead program and all other related pipeline development activity and engaged a financial advisory firm to explore its strategic alternatives, including evaluating a range of ways to generate value from the Company’s technology platform and intellectual property, its commercial and development capabilities, its listing on the Nasdaq Stock Market, and its remaining financial assets. Under the restructuring plan, the Company terminated the employment of 52 employees, or 90% of its workforce and recorded a restructuring charge during the nine months ended December 31, 2019 of approximately $2.8 million, primarily related to employee severance and benefits costs, of which $1.7 million was paid out during the fiscal second quarter, $0.9 million was paid out during the fiscal third quarter, and the remainder is anticipated to be paid out during the fiscal fourth quarter. The Company currently expects further restructuring actions tied to progress made on the strategic alternatives process, which could lead to an additional $3.5 million of severance and benefits costs that would be incurred and paid upon the closing of the Merger. Restructuring charges were recorded in selling, general and administrative expenses and were comprised of the following (in thousands): Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended December 31, 2019 December 31, 2018 December 31, 2019 December 31, 2018 Severance for Involuntary Employee Terminations $ 341 $ — $ 2,797 $ 428 Total Restructuring Expense $ 341 $ — $ 2,797 $ 428 The following table summarizes the activity and balances of the restructuring reserve (in thousands): Severance for Involuntary Employee Terminations Total Balance at March 31, 2019 $ — $ — Reserve established 2,456 2,456 Increase to reserve 341 341 Utilization of reserve: Payments (2,572 ) (2,572 ) Balance at December 31, 2019 $ 225 $ 225 The restructuring accrual is reflected on the condensed consolidated balance sheet at December 31, 2019 as accrued expenses.

Subsequent Events

Subsequent Events	9 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 10. Subsequent Events On January 26, 2020, the Company, its wholly owned subsidiary, Opal Merger Sub, Inc., and Tarveda entered into the First Amendment (the “Amendment”) to the Merger Agreement. The Amendment amends the definition of Organovo Valuation (as defined in the Merger Agreement) under the terms of the Merger Agreement to increase the Company’s valuation by $1.5 million for value attributable to the Company’s intellectual property if it does not sell or transfer its intellectual property and remaining assets prior to the closing of the Merger. The Organovo Valuation is used to calculate the Exchange Ratio (as defined in the Merger Agreement) between the Company and Tarveda stockholders. The Amendment also makes technical changes to the Organovo Stockholder Proposals (as defined in the Merger Agreement) to be voted on by the Company’s stockholders.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of presentation and principles of consolidation	Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not necessarily include all information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet at March 31, 2019 is derived from the Company’s audited consolidated balance sheet at that date. The unaudited condensed consolidated financial statements include the accounts of Organovo Holdings and its wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Company’s financial position, results of operations, stockholders’ equity and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2019, as filed with the Securities and Exchange Commission (“SEC”). Operating results for interim periods are not necessarily indicative of operating results for the Company’s fiscal year ending March 31, 2020 (see “ Note 1. Description of Business”
Liquidity	Liquidity As of December 31, 2019, the Company had cash and cash equivalents of approximately $30.5 million and restricted cash of approximately $0.1 million. The restricted cash was pledged as collateral for a letter of credit that the Company is required to maintain as a security deposit under the terms of the lease of its facilities. The Company had an accumulated deficit of approximately $276.7 million at December 31, 2019. The Company also had negative cash flows from operations of approximately $11.7 million during the nine months ended December 31, 2019. Through December 31, 2019, the Company has financed its operations primarily through the sale of convertible notes, warrants, the private placement of equity securities, the sale of common stock through public and at-the-market (“ATM”) offerings, and through revenue derived from product and research service-based agreements, collaborative agreements, licenses, and grants. During the three and nine months ended December 31, 2019, the Company issued 0 and 6,087,382 shares of its common stock through its ATM facility and received net proceeds of approximately $0 and $5.0 million, respectively. Throughout the strategic alternatives assessment process, the Company has taken steps to manage its resources and extend its cash runway including reducing commercial activities related to its liver tissues, except for sales of primary human cells out of inventory, negotiating an exit from its long-term facility lease, selling various assets, and reducing its workforce to the minimum level necessary to As a result, the Company terminated the employment of 52 employees, or 90% of its workforce and recorded a restructuring charge during the nine months ended December 31, 2019 of approximately $2.8 million, primarily related to employee severance and benefits costs, of which $1.7 million was paid out during the fiscal second quarter, $0.9 million was paid out during the fiscal third quarter, and the remainder is anticipated to be paid out during the fiscal fourth quarter. The Company currently expects further restructuring actions tied to the completion of the Merger with Tarveda, which could lead to an additional $3.5 million of severance and benefits costs that would The Company’s expenses may exceed its current plans and expectations, and, if the Merger with Tarveda is not completed, it could cause the Company to complete another transaction or wind-down its operations sooner than anticipated. If the Company is unable to successfully complete the Merger with Tarveda or another strategic transaction or secure additional capital on a timely basis and on terms that are acceptable to its stockholders, the Company may elect to cease its operations altogether, in which event the value realized by its stockholders might be significantly less than the $29.0 million of stockholders’ equity recorded on the Company’s consolidated financial statements as of December 31, 2019. While the Company believes that it can maintain its current operations for at least the next 12 months, based on its current plans and available resources, the assessment by the Company discussed above with respect to the Merger with Tarveda and other alternatives raises substantial doubt over the Company’s ability to successfully finance itself on a long-term basis. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Use of estimates	Use of estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates used in preparing the condensed consolidated financial statements include those assumed in revenue recognition, the measurement of operating lease right-of-use assets and lease liabilities, the valuation of stock-based compensation expense, the valuation of impairment of long-lived assets, and the valuation allowance on deferred tax assets. On an ongoing basis, management reviews these estimates and assumptions. Impairment of long-lived assets In accordance with ASC 360-10, the Company records an impairment loss on long-lived assets used in operations when events and circumstances indicate that long-lived assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets (i.e. not able to be recovered). During the second quarter of Fiscal 2020, the Company announced the restructuring of its operations. This event required the reevaluation of the recoverability of the gross carrying value of its long-lived assets. Upon the Company’s announcement and at each quarter-end, the Company performed an asset impairment analysis on its long-lived asset group, consisting primarily of licensed intangible assets, computer equipment, and software following the completion of various asset sales prior to December 31, 2019, which concluded that the carrying amount is not recoverable. However, the Company’s analysis indicated that carrying amount of the asset group does not exceed its fair value. As such, no impairment loss is required to be recognized. Nonetheless, it is reasonably possible that the impairment analysis may change in the near term resulting in the need to write down those assets to fair value. The Company will continue to monitor assets for impairment.
Revenue recognition	Revenue recognition The Company has generated revenues from payments received from research service agreements, product sales, collaborative agreements with partners including pharmaceutical and biotechnology companies and academic institutions, licenses, and grants from the National Institutes of Health (“NIH”) and private not-for-profit organizations. The Company recognizes revenue under Topic 606, Revenue from Contracts with Customers Billings to customers or payments received from customers are included in deferred revenue on the balance sheet until all revenue recognition criteria are met. As of December 31, 2019 and March 31, 2019, the Company had approximately $0 and $525,000, respectively, in deferred revenue related to its research service agreements, collaborative agreements, and licenses within the scope of Topic 606. In the nine months ended December 31, 2019, the Company recognized revenue on approximately $525,000, of which $490,000 related to the expiration of an agreement with a non-refundable up-front fee, that had been recorded as deferred revenue at March 31, 2019. Service revenues The Company’s service-based business, Organovo, Inc., utilized its NovoGen® bioprinting platform to provide customers access to its highly specialized tissues that model human biology and disease, and to in vitro For service contracts, the Company allocated the transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. If the standalone selling price was not observable through past transactions, the Company estimated the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The transaction price for service business contracts was a fixed consideration. In connection to the Company’s decision to pursue its strategic alternatives, the Company reduced commercial activities related to its liver tissues, except for sales of primary human cells out of inventory. The Company is expected to continue to maintain its external research collaborations and its intellectual property portfolio through the closing of the Merger. Product sales, net The Company’s product-based business, Samsara Sciences, Inc., produced high-quality cell-based products for use in Organovo’s 3D tissue manufacturing and for use by life science customers. The Company recognizes product revenue when the performance obligation is satisfied, which is at the point in time the customer obtains control of the Company’s product, typically upon delivery. Product revenues are recorded at the transaction price, net of any estimates for variable consideration under Topic 606. The Company’s process for estimating variable consideration does not differ materially from its historical practices. Variable consideration is estimated using the expected value method which considers the sum of probability-weighted amounts in a range of possible amounts under the contract. Product revenue reflects the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the individual contracts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. The Company provides no right of return to its customers except in cases where a customer obtains authorization from the Company for the return. To date, there have been no product returns. The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and adjusts its estimates accordingly. On November 7, 2019, the Company entered into an agreement to sell substantially all of the Samsara inventory and associated assets for $1.5 million, which was recorded to other income. As a result, the Company will have no further product sales of cells nor tissues beyond what it sold prior to the November 7 th Collaborative research, development, and licenses The Company has entered into collaborative agreements with partners that typically include one or more of the following: (i) non-exclusive license fees; (ii) non-refundable up-front fees; (iii) payments for reimbursement of research costs; (iv) payments associated with achieving specific development milestones; and (v) royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company has analyzed whether it results in a contract with a customer under Topic 606 or in an arrangement with a collaborator subject to guidance under ASC 808, Collaborative Arrangements The Company has considered a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements are distinct performance obligations, whether there are determinable stand-alone prices, and whether any licenses are functional or symbolic. The Company has evaluated each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, non-exclusive license fees, non-refundable upfront fees, and funding of research activities have been considered fixed, while milestone payments have been identified as variable consideration which must be evaluated to determine if it has been constrained and, therefore, excluded from the transaction price. The Company’s collaborative agreements that were not completed at the implementation of Topic 606 on April 1, 2018, consisted of research collaboration and limited technology access licenses. These agreements provide the licensee with a non-exclusive, non-transferable, limited, royalty-free technology license, including access to Organovo’s proprietary bioprinter platform, training, and continued support by means of consumables and consultation throughout the duration of the contract. The Company has determined that the intellectual property license is not distinct from the continued support promised under the agreement and is therefore a single combined performance obligation. The Company recognized revenue for these combined performance obligations over time for the duration of the license period, as the combined performance obligation would not be fully satisfied until the end of the contract. For the nine months ended December 31, 2019, all collaborations and licenses revenue was within the scope of Topic 606 and recognized accordingly. As of September 30, 2019, the Company completed its obligations under the existing agreements with respect to receipts of revenue and does not anticipate recording any further revenue. Grant revenue In July 2017, the NIH awarded the Company a “Research and Development” grant totaling approximately $1,657,000 of funding over three years. The Company has concluded this government grant is not within the scope of Topic 606, as government entities do not meet the definition of a “customer” as defined by Topic 606, as there is not considered to be a transfer of control of goods or services to the government entity funding the grant. Additionally, the Company has concluded this government grant does meet the definition of a contribution and is a non-reciprocal transaction, however, Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition does not apply, as the Company is a business entity and the grant is with a governmental agency. Revenues from this grant have been based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue has been recognized as the Company incurs expenses that are related to the grant. T he Company believes this policy is consistent with the overarching premise in Topic 606, to ensure that it recognizes revenues to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services, even though there is no “exchange” as defined in the ASC. The Company believes the recognition of revenue as costs are incurred and amounts become earned/realizable is analogous to the concept of transfer of control of a service over time under Topic 606. As of December 31, 2019, the Company has recognized approximately $1.2 million in grant revenue. Revenue recognized under this grant was approximately $0 and $52,000 for the three and nine months ended December 31, 2019, respectively. Revenue recognized under this grant was approximately $66,000 and $574,000 for the three and nine months ended December 31, 2018, respectively. In connection to the Company’s decision to pursue its strategic alternatives, specific to the NIH NASH grant, all internal research activities have been halted, leaving a remaining available balance of approximately $0.5 million that will not be utilized by the Company.
Cost of revenues	Cost of revenues The Company reported approximately less than $0.1 million and $0.3 million in cost of revenues for the three and nine months ended December 31, 2019, respectively, which includes an inventory write-off during the fiscal second quarter of approximately $0.2 million consisting of raw materials related to the Company’s bioprinting and testing services and is a result of the Company’s decision to pursue its strategic alternatives. The Company reported approximately $0.1 million and $0.4 million in cost of revenues for the three and nine months ended December 31, 2018, respectively. Cost of revenues consists of costs related to manufacturing and delivering product and service revenue.
Net loss per share	Net loss per share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options and warrants, shares reserved for purchase under the Company’s 2016 Employee Stock Purchase Plan (“ESPP”), the assumed release of restriction of restricted stock units, and shares subject to repurchase as the effect would be anti-dilutive. No dilutive effect was calculated for the three and nine months ended December 31, 2019 or 2018, as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. Common stock equivalents excluded from computing diluted net loss per share were approximately 16.7 million at December 31, 2019 and 15.6 million at December 31, 2018.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption. Adoption of New Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases (“ASC 842”), which supersedes the lease guidance under ASC 840 – Leases. The new accounting standard requires an entity to recognize right-of-use assets and corresponding lease liabilities on the balance sheet for all leases with terms of more than 12 months and to disclose key information about leasing arrangements. This new guidance became effective for the Company on April 1, 2019. The Company adopted ASC 842 on April 1, 2019 and elected the optional transition method that allows for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior periods. The Company elected the package of practical expedients permitted under the transition guidance, but not the hindsight practical expedient. Please refer to “Note 6. Leases” for more information regarding the Company’s adoption of the new lease standard. In February 2018, the FASB issued ASU No. 2018-02, Income Statement – Reporting Comprehensive Income In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting Recent Accounting Pronouncements Not Yet Adopted In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Dec. 31, 2019
Class Of Stock [Line Items]
Schedule of Stock-based Compensation Expense	Stock-based compensation expense for all stock-based awards consists of the following (in thousands): Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended December 31, 2019 December 31, 2018 December 31, 2019 December 31, 2018 Research and development $ 66 $ 249 $ 240 $ 679 General and administrative $ 1,186 $ 1,109 $ 3,468 $ 3,232 Total $ 1,252 $ 1,358 $ 3,708 $ 3,911
Fair Value of Employee Stock Options	The fair value of stock options was estimated at the grant date using the following weighted average assumptions: Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended December 31, 2019 * December 31, 2018 December 31, 2019 December 31, 2018 Dividend yield — — — — Volatility 0.00 % 73.07 % 84.36 % 72.99 % Risk-free interest rate 0.00 % 2.79 % 1.53 % 2.75 % Expected life of options — 6.00 years 6.00 years 6.00 years Weighted average grant date fair value $ — $ 0.67 $ 0.23 $ 0.84 *No options were granted in the three months ended December 31, 2019.
Fair Value of Employee Stock Purchase Plan	The fair value of ESPP shares was estimated at the purchase period commencement date using the following assumptions: Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended December 31, 2019* December 31, 2018 December 31, 2019* December 31, 2018 Dividend yield — — — — Volatility 0.00 % 80.23 % 43.69 % 61.35 - 80.23% Risk-free interest rate 0.00 % 2.29 % 2.52 % 1.85 - 2.29% Expected term — 6 months 6 months 6 months Grant date fair value $ — $ 0.45 $0.29 $0.30 - $0.45 *There are no participants in the ESPP for the current purchase period (beginning September 1, 2019).
Summary of Stock Option Activity	A summary of the Company’s stock option activity from March 31, 2019 to December 31, 2019 is as follows: Options Outstanding Weighted Average Exercise Price Aggregate Intrinsic Value Outstanding at March 31, 2019 12,039,264 $ 2.24 $ — Options granted 342,500 $ 0.32 $ — Options cancelled / forfeited (3,015,090 ) $ 2.68 $ — Options exercised — $ — $ — Outstanding at December 31, 2019 9,366,674 $ 2.02 $ 23,322 Vested and Exercisable at December 31, 2019 4,019,674 $ 2.73 $ —
Summary of Warrant Activity	The following table summarizes warrant activity for the nine months ended December 31, 2019: Warrants Weighted Average Exercise Price Balance at March 31, 2019 145,000 $ 7.11 Granted — $ — Exercised — $ — Cancelled (145,000 ) $ 7.11 Balance at December 31, 2019 — $ —
Common Stock Reserved for Future Issuance	Common stock reserved for future issuance consisted of the following at December 31, 2019: Common stock options outstanding and reserved under the 2012 Plan 6,547,442 Common stock reserved under the 2012 Plan 10,482,484 Common stock reserved under the 2016 Employee Stock Purchase Plan 1,188,718 Restricted stock units outstanding under the 2012 Plan 987,775 Performance-based restricted stock units outstanding under the 2012 Plan 6,027,899 Common stock options outstanding and reserved under the Incentive Award Agreement 2,819,232 Restricted stock units outstanding under the Incentive Award Agreement 120,535 Performance-based restricted stock units outstanding under the Incentive Award Agreement 158,706 Total at December 31, 2019 28,332,791
Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Summary of Company's Restricted Stock Units Activity and Performance Based Restricted Stock Units Activity	A summary of the Company’s restricted stock units (not including performance-based restricted stock units) activity from March 31, 2019 through December 31, 2019 is as follows: Number of Shares Weighted Average Price Unvested at March 31, 2019 2,080,723 $ 1.80 Granted 585,926 $ 0.97 Vested (500,666 ) $ 2.26 Cancelled / forfeited (1,057,673 ) $ 1.23 Unvested at December 31, 2019 1,108,310 $ 1.70
Performance-Based Restricted Stock Units [Member]
Class Of Stock [Line Items]
Summary of Company's Restricted Stock Units Activity and Performance Based Restricted Stock Units Activity	A summary of the Company’s performance-based restricted stock unit activity from March 31, 2019 through December 31, 2019 is as follows: Number of Shares Weighted Average Price Unvested at March 31, 2019 158,706 $ 1.04 Granted 6,027,899 $ 0.49 Vested — $ — Cancelled / forfeited — $ — Unvested at December 31, 2019 6,186,605 $ 0.50

Leases (Tables)

Leases (Tables)	9 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Schedule of Impact of Adoption of ASC 842 on Consolidated Balance Sheet	The impact of the adoption of ASC 842 on the consolidated balance sheet as of April 1, 2019 is as follows (in thousands): ASC 840 ASC 842 March 31, 2019 Impact of Adoption April 1, 2019 Deferred Rent $ 35 $ (35 ) $ — Deferred Rent, net of current portion $ 588 $ (588 ) $ — Prepaid Rent $ 88 $ (88 ) $ — Operating right-of-use assets $ — $ 4,451 $ 4,451 Operating lease liability $ — $ 1,038 $ 1,038 Operating lease liability, net of current portion $ — $ 3,948 $ 3,948
Summary of Cash Flows Associated with Company's Leases	The table below is a summary of the cash flows associated with the Company’s leases for the nine months ended December 31, 2019 (in thousands): For the Nine Months Ended December 31, 2019 Cash paid for amount included in measurement of liabilities: Operating cash flows from operating leases $ 579

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Dec. 31, 2019
Restructuring And Related Activities [Abstract]
Summary of Restructuring Charges Recorded in Selling, General and Administrative Expenses	Restructuring charges were recorded in selling, general and administrative expenses and were comprised of the following (in thousands): Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended December 31, 2019 December 31, 2018 December 31, 2019 December 31, 2018 Severance for Involuntary Employee Terminations $ 341 $ — $ 2,797 $ 428 Total Restructuring Expense $ 341 $ — $ 2,797 $ 428
Summary of Activity and Balances of Restructuring Reserve	The following table summarizes the activity and balances of the restructuring reserve (in thousands): Severance for Involuntary Employee Terminations Total Balance at March 31, 2019 $ — $ — Reserve established 2,456 2,456 Increase to reserve 341 341 Utilization of reserve: Payments (2,572 ) (2,572 ) Balance at December 31, 2019 $ 225 $ 225

Description of Business - Addit

Description of Business - Additional Information (Detail)	Jan. 26, 2020USD ($)	Dec. 13, 2019USD ($)	Nov. 07, 2019USD ($)	Dec. 31, 2019Employee
Description Of Business [Line Items]
Merger agreement date		Dec. 13, 2019
Amendment to merger agreement date				Jan. 26, 2020
Number of general and administrative personnel not terminated | Employee				6
Samsara [Member] | LifeNet Health [Member]
Description Of Business [Line Items]
Sale agreement date			Nov. 7, 2019
Sale of equipment and inventory in cash			$ 1,500,000
Merger Termination [Member] | Minimum [Member]
Description Of Business [Line Items]
Merger termination fee		$ 1,000,000
Reimbursement of expenses		300,000
Merger Termination [Member] | Maximum [Member]
Description Of Business [Line Items]
Merger termination fee		2,000,000
Reimbursement of expenses		500,000
Tarveda Therapeutics, Inc [Member]
Description Of Business [Line Items]
Net cash balance on upward and downward adjustment		22,000,000
Merger agreement upward and downward adjustment below description				If the Company’s net cash balance at the closing of the Merger is below $22 million, the Merger Agreement provides for adjusting the exchange ratio to increase the number of shares of its common stock issued to former Tarveda securityholders. As a result, Tarveda’s securityholders may receive additional shares of the Company’s common stock as Merger consideration, and consequently the Company’s securityholders may be further diluted as a result of the Merger.
Merger agreement upward and downward adjustment above description				If the Company’s net cash balance at the closing of the Merger is above $22 million, the Merger Agreement provides for adjusting the conversion ratio to decrease the number of shares of its common stock issued to former Tarveda securityholders.
Net cash balance at closing of merger		$ 15,000,000
Merger agreement description				If Tarveda’s net cash balance at the closing of the Merger is below $15 million, the Company may elect to not consummate the Merger.
Number of general and administrative personnel not terminated | Employee				6
Tarveda Therapeutics, Inc [Member] | Subsequent Event [Member]
Description Of Business [Line Items]
Amount credited to stockholders in connection with merger agreement	$ 1,500,000
Tarveda Therapeutics, Inc [Member] | Merger Agreement [Member]
Description Of Business [Line Items]
Percentage of ownership on pro forma basis		75.00%
Percentage of ownership by company's security holders		25.00%

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail)	Nov. 07, 2019USD ($)	Jul. 31, 2017USD ($)	Dec. 31, 2019USD ($)Employeeshares	Sep. 30, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2019USD ($)Employeeshares	Dec. 31, 2018USD ($)shares	Dec. 31, 2019USD ($)Employee	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)
Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents			$ 30,467,000		$ 35,224,000	$ 30,467,000	$ 35,224,000	$ 30,467,000		$ 36,477,000
Restricted cash			100,000			100,000		100,000
Accumulated deficit			$ (276,742,000)			(276,742,000)		$ (276,742,000)		(260,755,000)
Cash flow from operations						$ 11,673,000	15,298,000
Number of employees terminated | Employee						52
Percentage of workforce terminated						90.00%
Restructuring charges						$ 2,456,000
Payments for restructuring						2,572,000
Severance and benefits costs						$ 3,500,000
Number of general and administrative personnel | Employee			6			6		6
Stockholders’ equity			$ 28,954,000			$ 28,954,000		$ 28,954,000		36,298,000
Impairment of long-lived assets						0
Deferred revenue			0			0		0		525,000
Revenue recognized						525,000
Sale of inventory and associated assets						728,000	3,000
Revenue recognized under grants			298,000		779,000	2,196,000	2,411,000
Cost of revenues					100,000	300,000	400,000
Inventory write-off				$ 200,000		214,000	0
Dilutive effect			0		0	$ 0	$ 0
Common stock equivalents excluded from computing diluted net loss per share | shares						16,700,000	15,600,000
NIH Research Grants Two [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue recognized under grants		$ 1,657,000
Grant revenue funding period		3 years
Other Income [Member]
Summary Of Significant Accounting Policies [Line Items]
Sale of inventory and associated assets	$ 1,500,000
Product [Member]
Summary Of Significant Accounting Policies [Line Items]
Product return revenue						$ 0
Grants [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue recognized under grants			0		66,000	52,000	$ 574,000
Revenue unutilized remaining available balance						500,000
Grants [Member] | NIH Research Grants Two [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue related to expiration of an agreement								1,200,000
Revenue recognized under grants			0		$ 66,000	52,000	$ 574,000
Expiration Agreement [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue related to expiration of an agreement						490,000
Research and Development Services [Member]
Summary Of Significant Accounting Policies [Line Items]
Deferred revenue			0			0		0		$ 525,000
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Stockholders’ equity			29,000,000			29,000,000		$ 29,000,000
Cost of revenues			$ 100,000
Tarveda Therapeutics, Inc [Member]
Summary Of Significant Accounting Policies [Line Items]
Severance and benefits costs						$ 3,500,000
Number of general and administrative personnel | Employee			6			6		6
Transaction related costs			$ 4,200,000			$ 4,200,000		$ 4,200,000
Scenario, Forecast [Member]
Summary Of Significant Accounting Policies [Line Items]
Cash balance									$ 29,000,000
Employee Severance and Benefits Costs [Member]
Summary Of Significant Accounting Policies [Line Items]
Restructuring charges						$ 2,800,000
Payments for restructuring			$ 900,000	$ 1,700,000
At-The-Market Facility [Member]
Summary Of Significant Accounting Policies [Line Items]
Issuance of common stock | shares			0			6,087,382
Gross proceeds from sale of common stock shares			$ 0			$ 5,000,000

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,252	$ 1,358	$ 3,708	$ 3,911
Research and development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	66	249	240	679
General and administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,186	$ 1,109	$ 3,468	$ 3,232

Stockholders' Equity - Stock-ba

Stockholders' Equity - Stock-based Compensation Expense and Valuation Information - Additional Information (Detail)	9 Months Ended
	Dec. 31, 2019USD ($)Participant
Class Of Stock [Line Items]
Total unrecognized compensation cost related to unvested stock option grants	$ 4,855,000
Participants enrolled into the employee stock purchase plan | Participant	0
Stock options [Member]
Class Of Stock [Line Items]
Total unrecognized compensation cost related, weighted average period	2 years 1 month 13 days
Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Total unrecognized compensation cost related, weighted average period	1 year 11 months 19 days
Unrecognized stock-based compensation expense	$ 1,642,000
Performance-Based Restricted Stock Units [Member]
Class Of Stock [Line Items]
Total unrecognized compensation cost related, weighted average period	1 year 7 months 6 days
Unrecognized stock-based compensation expense	$ 2,339,000

Stockholders' Equity - Fair Val

Stockholders' Equity - Fair Value of Employee Stock Options (Detail) - $ / shares	3 Months Ended			9 Months Ended
	Dec. 31, 2019	[1]	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Dividend yield	0.00%		0.00%	0.00%	0.00%
Volatility	0.00%		73.07%	84.36%	72.99%
Risk-free interest rate	0.00%		2.79%	1.53%	2.75%
Expected life of options			6 years	6 years	6 years
Weighted average grant date fair value	$ 0		$ 0.67	$ 0.23	$ 0.84
[1]	No options were granted in the three months ended December 31, 2019.

Stockholders' Equity - Fair V_2

Stockholders' Equity - Fair Value of Employee Stock Options (Parenthetical) (Detail) - shares	3 Months Ended	9 Months Ended
	Dec. 31, 2019	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of options granted	0	342,500

Stockholders' Equity - Fair V_3

Stockholders' Equity - Fair Value of Employee Stock Purchase Plan (Detail) - $ / shares	3 Months Ended			9 Months Ended
	Dec. 31, 2019		Dec. 31, 2018	Dec. 31, 2019		Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%	[1]	0.00%	0.00%		0.00%
Volatility	0.00%	[1]	73.07%	84.36%		72.99%
Risk-free interest rate	0.00%	[1]	2.79%	1.53%		2.75%
Expected term			6 years	6 years		6 years
Grant date fair value	$ 0	[1]	$ 0.67	$ 0.23		$ 0.84
2016 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%	[2]	0.00%	0.00%	[2]	0.00%
Volatility	0.00%	[2]	80.23%	43.69%	[2]
Risk-free interest rate	0.00%	[2]	2.29%	2.52%	[2]
Expected term			6 months	6 months	[2]	6 months
Grant date fair value	$ 0	[2]	$ 0.45	$ 0.29	[2]
2016 Employee Stock Purchase Plan [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Volatility						61.35%
Risk-free interest rate						1.85%
Grant date fair value						$ 0.30
2016 Employee Stock Purchase Plan [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Volatility						80.23%
Risk-free interest rate						2.29%
Grant date fair value						$ 0.45
[1]	No options were granted in the three months ended December 31, 2019.
[2]	There are no participants in the ESPP for the current purchase period (beginning September 1, 2019).

Stockholders' Equity - Fair V_4

Stockholders' Equity - Fair Value of Employee Stock Purchase Plan (Parenthetical) (Detail)	Dec. 31, 2019Participant
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Participants enrolled into the employee stock purchase plan	0
2016 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Participants enrolled into the employee stock purchase plan	0

Stockholders' Equity - Preferre

Stockholders' Equity - Preferred Stock - Additional Information (Detail)	Dec. 31, 2019shares
Equity [Abstract]
Preferred stock, shares authorized	25,000,000
Preferred stock, shares outstanding	0

Stockholders' Equity - Common S

Stockholders' Equity - Common Stock - Additional Information (Detail) - USD ($)	Jun. 25, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Sep. 30, 2020	Mar. 31, 2019	Jul. 26, 2018	Mar. 16, 2018
Class Of Stock [Line Items]
Issuance of common stock		130,497,563		130,497,563			124,015,429
Common stock, shares authorized		200,000,000		200,000,000			200,000,000
Certificate of Amendment [Member]
Class Of Stock [Line Items]
Common stock, shares authorized								200,000,000
Minimum [Member]
Class Of Stock [Line Items]
Minimum closing bid price	$ 1,000,000
2018 Sales Agreement [Member]
Class Of Stock [Line Items]
Equity sales agreement expiration date				Feb. 22, 2021
Value of shares sold under equity distribution agreement				$ 18,700,000
Issuance of common stock		17,719,185		17,719,185
2018 Sales Agreement [Member] | Maximum [Member]
Class Of Stock [Line Items]
Common stock value reserved for future issuance		$ 81,300,000		$ 81,300,000
IPO [Member]
Class Of Stock [Line Items]
Securities authorized for offer and sale, amount						$ 100,000,000
At-The-Market Facility [Member]
Class Of Stock [Line Items]
Issuance of common stock from stock options exercises, net, Shares		0		6,087,382
At-The-Market Facility [Member] | 2018 Sales Agreement [Member]
Class Of Stock [Line Items]
Common stock value reserved for future issuance		$ 31,300,000		$ 31,300,000
Issuance of common stock from stock options exercises, net, Shares		0	1,798,384	6,087,382	5,560,514
Value of shares sold under equity distribution agreement		$ 0	$ 1,900,000	$ 5,000,000	$ 6,900,000
At-The-Market Facility [Member] | 2018 Sales Agreement [Member] | Maximum [Member]
Class Of Stock [Line Items]
Common stock value reserved for future issuance									$ 50,000,000

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Company's Restricted Stock Units Activity and Performance-Based Restricted Stock Units Activity (Detail)	9 Months Ended
	Dec. 31, 2019$ / sharesshares
Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Beginning balance, Unvested, Number of Shares | shares	2,080,723
Granted, Number of Shares | shares	585,926
Vested, Number of Shares | shares	(500,666)
Canceled / forfeited, Number of Shares | shares	(1,057,673)
Ending balance, Unvested, Number of Shares | shares	1,108,310
Beginning balance, Unvested, Weighted Average Price | $ / shares	$ 1.80
Granted, Weighted Average Price | $ / shares	0.97
Vested, Weighted Average Price | $ / shares	2.26
Canceled / forfeited, Weighted Average Price | $ / shares	1.23
Ending balance, Unvested, Weighted Average Price | $ / shares	$ 1.70
Performance-Based Restricted Stock Units [Member]
Class Of Stock [Line Items]
Beginning balance, Unvested, Number of Shares | shares	158,706
Granted, Number of Shares | shares	6,027,899
Vested, Number of Shares | shares	0
Canceled / forfeited, Number of Shares | shares	0
Ending balance, Unvested, Number of Shares | shares	6,186,605
Beginning balance, Unvested, Weighted Average Price | $ / shares	$ 1.04
Granted, Weighted Average Price | $ / shares	0.49
Vested, Weighted Average Price | $ / shares	0
Canceled / forfeited, Weighted Average Price | $ / shares	0
Ending balance, Unvested, Weighted Average Price | $ / shares	$ 0.50

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted Stock Awards, Restricted Stock Units and Performance-Based Restricted Stock Units - Additional Information (Detail)	Jul. 02, 2019shares	Dec. 12, 2018shares	Aug. 23, 2017USD ($)Trancheshares	Dec. 31, 2019Trancheshares	Apr. 24, 2017shares
Inducement Award Performance-Based Restricted Stock Units [Member]
Class Of Stock [Line Items]
Number of tranches | Tranche			5
Award vesting percentage		100.00%
Number of tranches expected to vest | Tranche				0
Grant date fair values of tranches | $			$ 165,000
Inducement Award Performance-Based Restricted Stock Units [Member] | Maximum [Member]
Class Of Stock [Line Items]
Number of shares allocated			208,822
Inducement Award Performance-Based Restricted Stock Units [Member] | Share-based Compensation Award, Tranche One [Member]
Class Of Stock [Line Items]
Award vesting percentage			20.00%
Stock units vesting year			2018
Inducement Award Performance-Based Restricted Stock Units [Member] | Share-based Compensation Award, Tranche One [Member] | Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage			0.00%
Inducement Award Performance-Based Restricted Stock Units [Member] | Share-based Compensation Award, Tranche One [Member] | Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage			120.00%
Inducement Award Performance-Based Restricted Stock Units [Member] | Share-based Compensation Award, Tranche Two [Member]
Class Of Stock [Line Items]
Award vesting percentage			20.00%
Stock units vesting year			2019
Inducement Award Performance-Based Restricted Stock Units [Member] | Share-based Compensation Award, Tranche Two [Member] | Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage			0.00%
Inducement Award Performance-Based Restricted Stock Units [Member] | Share-based Compensation Award, Tranche Two [Member] | Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage			120.00%
Inducement Award Performance-Based Restricted Stock Units [Member] | Share-based Compensation Award, Tranche Three [Member]
Class Of Stock [Line Items]
Award vesting percentage			20.00%
Stock units vesting year			2020
Inducement Award Performance-Based Restricted Stock Units [Member] | Share-based Compensation Award, Tranche Three [Member] | Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage			0.00%
Inducement Award Performance-Based Restricted Stock Units [Member] | Share-based Compensation Award, Tranche Three [Member] | Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage			120.00%
Inducement Award Performance-Based Restricted Stock Units [Member] | Share Based Compensation Award Tranche Four [Member]
Class Of Stock [Line Items]
Award vesting percentage			20.00%
Stock units vesting year			2021
Inducement Award Performance-Based Restricted Stock Units [Member] | Share Based Compensation Award Tranche Four [Member] | Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage			0.00%
Inducement Award Performance-Based Restricted Stock Units [Member] | Share Based Compensation Award Tranche Four [Member] | Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage			120.00%
Inducement Award Performance-Based Restricted Stock Units [Member] | Share Based Compensation Award Tranche Five [Member]
Class Of Stock [Line Items]
Award vesting percentage			20.00%
Stock units vesting year			2020
Share based compensation arrangement, number of shares vested		41,764
Share based compensation arrangement, number of shares forfeited		8,352
Share based compensation arrangement, number of shares eligible to vest upon future performance				158,706
Share based compensation arrangement amendment description and terms				Based on the amendment to the vesting criteria, the remaining 158,706 units eligible to vest upon future performance were divided into three separate but equal tranches with independent vesting criteria based on the achievement of certain regulatory milestones.
Inducement Award Performance-Based Restricted Stock Units [Member] | Share Based Compensation Award Tranche Five [Member] | Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage			0.00%
Inducement Award Performance-Based Restricted Stock Units [Member] | Share Based Compensation Award Tranche Five [Member] | Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage			120.00%
Inducement Award Performance-Based Restricted Stock Units [Member] | CEO [Member]
Class Of Stock [Line Items]
Number of shares allocated					208,822
PBRSU Retention Awards [Member] | Management Team [Member]
Class Of Stock [Line Items]
Number of shares allocated	6,027,899
Performance based restricted stock unit award vesting period	24 months

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Stock Option Activity (Detail)	3 Months Ended	9 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options Outstanding, Beginning balance | shares		12,039,264
Granted, Options Outstanding | shares	0	342,500
Cancelled / forfeited, Options Outstanding | shares		(3,015,090)
Exercised, Options Outstanding | shares		0
Options Outstanding, Ending balance | shares	9,366,674	9,366,674
Vested and Exercisable, Options Outstanding | shares	4,019,674	4,019,674
Weighted-Average Exercise Price, Options Beginning balance | $ / shares		$ 2.24
Options granted, Weighted-Average Exercise Price | $ / shares		0.32
Options cancelled / forfeited, Weighted-Average Exercise Price | $ / shares		2.68
Options exercised, Weighted-Average Exercise Price | $ / shares		0
Weighted-Average Exercise Price, Options Ending balance | $ / shares	$ 2.02	2.02
Vested and Exercisable, Weighted-Average Exercise Price | $ / shares	$ 2.73	$ 2.73
Aggregate Intrinsic Value, Options Beginning balance | $		$ 0
Options Exercised, Aggregate Intrinsic Value | $		0
Aggregate Intrinsic Value, Options | $	$ 23,322	23,322
Vested and Exercisable, Aggregate Intrinsic Value | $	$ 0	$ 0

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Dec. 31, 2018	Dec. 31, 2019		Dec. 31, 2018
Class Of Stock [Line Items]
Weighted-average remaining contractual term of options exercisable		7 years 2 months 23 days
Weighted-average remaining contractual term of options outstanding		7 years 2 months 23 days
Number of common stock shares approved under ESPP		28,332,791
Expected life of options	6 years	6 years		6 years
2016 Employee Stock Purchase Plan [Member]
Class Of Stock [Line Items]
Number of common stock shares approved under ESPP		1,500,000
Employee subscription rate		15.00%
Compensation amount per employee		$ 25,000
Number of shares per employee		10,000
Fair market value at discount		85.00%
Purchase period		6 months
Initial offering period		2016-09
Description of plan		Shares under the ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period.
Expected life of options	6 months	6 months	[1]	6 months
Shares available for purchase under ESPP		1,188,718
[1]	There are no participants in the ESPP for the current purchase period (beginning September 1, 2019).

Stockholders' Equity - Summar_3

Stockholders' Equity - Summary of Warrant Activity (Detail) - $ / shares	3 Months Ended	9 Months Ended
	Dec. 31, 2019	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Outstanding, Beginning balance		12,039,264
Granted, Options Outstanding	0	342,500
Exercised, Options Outstanding		0
Options Outstanding, Ending balance	9,366,674	9,366,674
Weighted-Average Exercise Price, Options Beginning balance		$ 2.24
Granted, Weighted-Average Exercise Price		0.32
Exercised, Weighted-Average Exercise Price		0
Weighted-Average Exercise Price, Options Ending balance	$ 2.02	$ 2.02
Warrants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Outstanding, Beginning balance		145,000
Granted, Options Outstanding		0
Exercised, Options Outstanding		0
Cancelled, Options Outstanding		(145,000)
Options Outstanding, Ending balance	0	0
Weighted-Average Exercise Price, Options Beginning balance		$ 7.11
Granted, Weighted-Average Exercise Price		0
Exercised, Weighted-Average Exercise Price		0
Cancelled, Weighted-Average Exercise Price		7.11
Weighted-Average Exercise Price, Options Ending balance	$ 0	$ 0

Stockholders' Equity - Warrants

Stockholders' Equity - Warrants - Additional Information (Detail)	Dec. 31, 2019shares
Equity [Abstract]
Warrants outstanding	0

Stockholders' Equity - Common_2

Stockholders' Equity - Common Stock Reserved for Future Issuance (Detail)	Dec. 31, 2019shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	28,332,791
Equity Incentive Plan 2012 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	10,482,484
2016 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	1,500,000
Stock options [Member] | Equity Incentive Plan 2012 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	6,547,442
Stock options [Member] | 2016 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	1,188,718
Stock options [Member] | Inducement Award Agreement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	2,819,232
Restricted stock units (RSUs) [Member] | Equity Incentive Plan 2012 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	987,775
Restricted stock units (RSUs) [Member] | Inducement Award Agreement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	120,535
Performance-Based Restricted Stock Units [Member] | Equity Incentive Plan 2012 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	6,027,899
Performance-Based Restricted Stock Units [Member] | Inducement Award Agreement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	158,706

Collaborative Research, Devel_2

Collaborative Research, Development, and License Agreements - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	May 31, 2018	Apr. 30, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues			$ 298,000	$ 779,000	$ 2,196,000	$ 2,411,000
Non-exclusive patent license agreement annual fee			13,000	136,000	328,000	381,000
April 2017 Non-exclusive Research Affiliation Collaborative [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Non-exclusive patent license agreement term		2 years
Proceeds from Non-exclusive patent annual license fee	$ 75,000	$ 75,000
Collaborations and Licenses [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues			70,000	43,000	89,000	128,000
Collaborations and Licenses [Member] | December 2016 Non-exclusive Research Affiliation Collaborative [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues			0	10,000	19,000	29,000
Collaborations and Licenses [Member] | April 2017 Non-exclusive Research Affiliation Collaborative [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues			0	18,000	0	56,000
Collaborations and Licenses [Member] | April 2017 Non-exclusive Research Affiliation Collaborative [Member] | Up-front Payment Received [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues			$ 0	$ 14,000	$ 0	$ 43,000
License [Member] | April 2017 Non-exclusive Research Affiliation Collaborative [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Non-exclusive patent license agreement annual fee		$ 75,000

Leases - Additional Information

Leases - Additional Information (Details)	Oct. 02, 2019USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2019USD ($)ft²	Dec. 31, 2018USD ($)	Apr. 01, 2019USD ($)	Mar. 31, 2019USD ($)	Mar. 21, 2019
Operating Lease [Line Items]
Operating right-of-use assets						$ 4,500,000	$ 0
Operating lease liability						5,000,000
Deferred rent						$ 600,000
Office space under lease agreement | ft²				45,580
Monthly rental payments				$ 87,000
Base rent escalators		3.00%		3.00%
Landlord tenant improvements funded amount				$ 500,000
Lease option termination description				option to terminate the lease on or after September 1, 2019 with 9 months prior written notice.
Right-of-use asset write-off		$ 26,000		$ 26,000
Lease liabilities write-off		26,000		26,000
Gain on lease termination		525,000	$ 0	525,000	$ 0
Lease term								36 months
Monthly rental payments	$ 4,000
Operating lease expense		45,000		568,000
Rent expense		7,000	$ 264,000	7,000	$ 915,000
Variable lease expense		65,000		302,000
Short term lease cost		0		$ 37,000
Main Facilities [Member]
Operating Lease [Line Items]
Lease expiration date				Nov. 15, 2019
Right-of-use asset write-off		4,100,000		$ 4,100,000
Lease liabilities write-off		4,600,000		$ 4,600,000
Gain on lease termination		$ 500,000
Lease Term For Remainder of Total Rentable Square Footage [Member]
Operating Lease [Line Items]
Lease expiration date				Aug. 31, 2024
Lease Term For 14,685 of Total Rentable Square Footage [Member]
Operating Lease [Line Items]
Office space under lease agreement | ft²				14,685
Lease expiration date				Oct. 31, 2018

Leases - Schedule of Impact of

Leases - Schedule of Impact of Adoption of ASC 842 on Consolidated Balance Sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Apr. 01, 2019	Mar. 31, 2019
Operating Lease [Line Items]
Deferred rent	$ 0		$ 35
Deferred rent, net of current portion	$ 0		588
Prepaid Rent			88
Operating right-of-use assets		$ 4,500	0
Operating lease liability			0
Operating lease liability, net of current portion			$ 0
ASC 842 [Member]
Operating Lease [Line Items]
Deferred rent		0
Deferred rent, net of current portion		0
Prepaid Rent		0
Operating right-of-use assets		4,451
Operating lease liability		1,038
Operating lease liability, net of current portion		3,948
Impact of Adoption [Member] | ASC 842 [Member]
Operating Lease [Line Items]
Deferred rent		(35)
Deferred rent, net of current portion		(588)
Prepaid Rent		(88)
Operating right-of-use assets		4,451
Operating lease liability		1,038
Operating lease liability, net of current portion		$ 3,948

Leases - Summary of Cash Flows

Leases - Summary of Cash Flows Associated with Company's Leases (Details) $ in Thousands	9 Months Ended
	Dec. 31, 2019USD ($)
Cash paid for amount included in measurement of liabilities:
Operating cash flows from operating leases	$ 579

Related Parties - Additional In

Related Parties - Additional Information (Detail) - USD ($)	Mar. 31, 2019	Nov. 30, 2019	Apr. 30, 2019	Nov. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Related Party Transaction [Line Items]
Sale of productive assets							$ 728,000	$ 3,000
Cirius Therapeutics, Inc., [Member] | Research Services [Member]
Related Party Transaction [Line Items]
Amount of transactions with related party for providing services							281,000
Revenue recognized from related parties agreement							281,000
Viscient Biosciences [Member]
Related Party Transaction [Line Items]
Revenue recognized from related parties agreement							70,000
Sale of productive assets		$ 171,000
Other income		$ 101,000
Viscient Biosciences [Member] | Research Services [Member]
Related Party Transaction [Line Items]
Amount of transactions with related party for providing services			$ 7,000	$ 142,000
Revenue recognized from related parties agreement	$ 42,000						107,000
Viscient Biosciences [Member] | Samsara [Member] | Primary Human Cell-based Products [Member]
Related Party Transaction [Line Items]
Revenue recognized from related parties agreement					$ 44,000	$ 88,000	$ 128,000	$ 91,000

Restructuring - Additional Info

Restructuring - Additional Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2019USD ($)	Sep. 30, 2019USD ($)	Dec. 31, 2019USD ($)Employee
Restructuring Cost And Reserve [Line Items]
Number of employees terminated | Employee			52
Percentage of workforce terminated			90.00%
Restructuring charges			$ 2,456
Payments for restructuring			2,572
Severance and benefits costs			3,500
Employee Severance and Benefits Costs [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring charges			$ 2,800
Payments for restructuring	$ 900	$ 1,700

Restructuring - Summary of Rest

Restructuring - Summary of Restructuring Charges Recorded in Selling, General and Administrative Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Restructuring Cost And Reserve [Line Items]
Severance for Involuntary Employee Terminations			$ 3,500
Total Restructuring Expense			2,456
Selling, General and Administrative Expenses [Member]
Restructuring Cost And Reserve [Line Items]
Severance for Involuntary Employee Terminations	$ 341	$ 0	2,797	$ 428
Total Restructuring Expense	$ 341	$ 0	$ 2,797	$ 428

Restructuring - Summary of Acti

Restructuring - Summary of Activity and Balances of Restructuring Reserve (Details) $ in Thousands	9 Months Ended
	Dec. 31, 2019USD ($)
Restructuring Cost And Reserve [Line Items]
Balance at March 31, 2019	$ 0
Reserve established	2,456
Increase to reserve	341
Utilization of reserve:
Payments	(2,572)
Balance at December 31, 2019	225
Severance for Involuntary Employee Terminations [Member]
Restructuring Cost And Reserve [Line Items]
Balance at March 31, 2019	0
Reserve established	2,456
Increase to reserve	341
Utilization of reserve:
Payments	(2,572)
Balance at December 31, 2019	$ 225

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) $ in Millions	Jan. 26, 2020USD ($)
Subsequent Event [Member] | Tarveda Therapeutics, Inc [Member]
Subsequent Event [Line Items]
Increase in valuation for value attributable to company’s intellectual property	$ 1.5